Health Technology Assessment Info Service

Public View

Tap into ECRI Institute's independent, unbiased expertise to make well-informed decisions regarding coverage and implementation of new and emerging drugs, health devices, procedures, and processes.

By providing high-quality information on clinical, safety, cost, and reimbursement data, ECRI Institute can help you bring in the technologies that make the most sense for your organization, your patient populations, and your bottom line.

Access up-to-date evidence reports and forecasts, engage with our experts in one-on-one consultations, or make custom, time-sensitive research requests on specific technologies and procedures.

Here's what one member has to say about ECRI Institute

Here's how you can reach your decisions quicker:

  • Let us research your product requests. Our on-site experts can perform time-intensive research while you focus on other tasks. Reports are delivered in time for your value analysis meetings.
  • Access thousands of reportsor make custom requests. Need to compare this technology to that technology? Check our database. If you can't find what you're looking for, simply tell us what you need and we'll get to work.
  • Monitor new and emerging technologies. Track health technologies so you can craft a strategic technology plan that fits your organization's vision.
  • Thrive with market intelligence. Use our reports to underpin coverage decisions, track market trendsincluding pricingon competing or disruptive technologies, and compare products.

Tour our capabilities, or better yet, call our staff

Learn more about how we can help you cut through the marketing hype and get to the evidence for better decision making.

Contact Us

I need help with...
Already a member? Log in here
Request More Information > ECRI Directory >

 Related Memberships & Services

 What you get as a member

An easily searchable online database of reportsand the ability to make custom requeststo help you make evidence-based decisions on technology along the continuum of evidence, from research and development to widespread diffusion. Our  multidisciplinary staff, which includes doctoral-level scientists, physicians, nurses, technologists, and research analysts, are just a phone call or e-mail away.

  • Cut through the hype and get evidence-based recommendations on brand-name drugs, devices, or tests that you’re considering
  • Get a roadmap to the literature on specific health technologies or services
  • See systematic reviews that provide a first look at the clinical evidence on newly approved technologies and procedures
  • Examine profiles of technologies under research and development and their potential impact on your facility
  • Track the latest healthcare technology developments with original monthly reporting featuring interviews with industry leaders

list of published ​topics

ECRI Institute provides broad access to technology assessment information and research results so that your conclusions about medical devices, drugs, and procedures can be drawn from the most comprehensive pool of findings available.

Download the list of published topics

 This membership

Component Image
Custom Product Briefs
On-demand short reports on brand-specific medical devices and pharmaceuticals
Component Image
Custom Rapid Reviews
On-demand technology- or topic-specific overviews and literature searches with summaries
Component Image
Emerging Technology Reports
Technology assessments of new and emerging drugs, devices, procedures, and services.
Component Image
Evidence Reports
Systematic reviews and comparative effectiveness reviews on widely diffused healthcare technologies.
Component Image
FDA Approvals & Clearances
Short descriptions of new drug, device, and biologic approvals with labeled indication and link to approval letter.
Component Image
Standards & Guidelines
Citations and links to clinical guidelines, technical standards, consensus statements, position papers, and healthcare laws.
Component Image
Technology Forecasts
Profiles with predictions of impacts of new and emerging healthcare drugs, devices, procedures
Component Image
Technology News
News articles on emerging medical technologies with original reporting and expert interviews.

 Case Studies

 Patient Resources

As part of our mission to improve patient care, we believe that patients should have access to reliable medical resources and safety information and have provided a number of free resources on our website. Click here to read more.

 Annual Health Policy Conference

Each year, ECRI Institute organizes an annual health policy conference delineating perspectives of stakeholders throughout the healthcare community in addressing broad issues about the science, evaluation of evidence, and the use of medical technology, pharmaceuticals, procedures, and health services.

Click here for a list of past conferences

 Sample Technology Trends

 

 

Too Many Knee Surgeries, Better Patient Evaluation Needed, Researchers Findhttps://www.ecri.org/components/Trends/Pages/14231.aspxToo Many Knee Surgeries, Better Patient Evaluation Needed, Researchers Find7/1/2014 12:00:00 AM​Up to one third of patients who receive knee replacement surgery don't need it, according to a recent retrospective study that highlights the need for an appropriate classification system for surgeons to evaluate patients.
Meaningful Use Stage 2 and Health Information Exchange standardized formatshttps://www.ecri.org/components/Trends/Pages/HTT1112_3.aspxMeaningful Use Stage 2 and Health Information Exchange standardized formats11/1/2012 12:00:00 AMThe Meaningful Use Stage 2 final rules define a common dataset for all Summary of Care records, including structured and coded data to be formatted uniformly.

 Sample Evidence Reports

 

 

Breast-Specific Gamma Imaging for Breast Cancerhttps://www.ecri.org/components/EvidenceReports/Pages/12861.aspxBreast-Specific Gamma Imaging for Breast Cancer3/22/2013 12:00:00 AM​This report examines the use of breast-specific gamma imaging (sometimes referred to as molecular breast imaging) for breast cancer; uses of this technology for other conditions, and other technologies used for breast cancer, are outside the scope of this report.

 Sample Emerging Technology Reports

 

 

Fecal Microbiota Transplantation for Treating Recurrent Clostridium difficile Infectionhttps://www.ecri.org/components/Target/Pages/12037.aspxFecal Microbiota Transplantation for Treating Recurrent Clostridium difficile Infection8/15/2014 12:00:00 AMFecal microbiota transplantation involves introducing saline-diluted fecal matter from a healthy donor into the gastrointestinal tract of a patient with recurrent Clostridium difficile infection. Does this treatment work? Is it safe? Will patients and clinicians accept this novel treatment option?

 Sample Technology Forecasts

 

 

Computed Tomography with Computer-aided Detection for Lung Cancer Screeninghttps://www.ecri.org/components/Forecast/Pages/5036.aspxComputed Tomography with Computer-aided Detection for Lung Cancer Screening2/9/2015 12:00:00 AMSeveral medical societies recommend annual lung cancer screening with low-dose computed tomography (LDCT) for certain individuals at high risk. However, the value of adding computer-aided detection to improve LDCT screening accuracy remains unclear.

 Sample Hotline Responses

 

 

Special Report: Risk of Uterine Cancer Dissemination after Laparoscopic Power Morcellation for Myomectomy and Hysterectomyhttps://www.ecri.org/components/Hotline/Documents/13825.pdfSpecial Report: Risk of Uterine Cancer Dissemination after Laparoscopic Power Morcellation for Myomectomy and Hysterectomy3/31/2015 12:00:00 AM​This Special Report updates and replaces our January 2015 Special Report on laparoscopic power morcellation. Laparoscopic hysterectomy (LH) involves placing a trocar at or above the umbilicus. Additional trocars are placed in the lower abdomen.
Automated Technologies for Patient Room Disinfection and Decontamination of Biosafety Level 4 Infectious Agents, Including Ebola Virushttps://www.ecri.org/components/Hotline/Pages/14374.aspxAutomated Technologies for Patient Room Disinfection and Decontamination of Biosafety Level 4 Infectious Agents, Including Ebola Virus12/22/2014 12:00:00 AM​We explore the literature on automated means of disinfecting patient rooms and the decontamination of Biosafety Level 4 infectious agents, including Ebola virus.
Rapid Point-of-care Tests for Diagnosing Ebola Virus Diseasehttps://www.ecri.org/components/Hotline/Pages/14373.aspxRapid Point-of-care Tests for Diagnosing Ebola Virus Disease11/24/2014 12:00:00 AM​In our efforts to monitor developments in Ebola treatment, we examine the literature on rapid point-of-care testing, which is intended for use in various settings proximal to a patient, such as at the bedside, in the home, or in the ER, which may of particular utility in developing nations.

 Sample Product Briefs

 

 

ReEBOV Antigen Rapid Test (Corgenix Medical Corp.) for Diagnosing Ebola Virus Diseasehttps://www.ecri.org/components/ProductBriefs/Pages/23488.aspxReEBOV Antigen Rapid Test (Corgenix Medical Corp.) for Diagnosing Ebola Virus Disease3/13/2015 12:00:00 AM​The ReEBOV™ Antigen Rapid Test is a point-of-care assay intended to quickly diagnose Ebola virus disease in patients with signs and symptoms who may have been exposed to the virus. FDA granted Emergency Use Authorization for the test in February 2015 to detect the Zaire strain.
Ebola Vaccine Candidate cAd3-EBO (GlaxoSmithKline) for Preventing Ebola Virus Diseasehttps://www.ecri.org/components/ProductBriefs/Pages/14467.aspxEbola Vaccine Candidate cAd3-EBO (GlaxoSmithKline) for Preventing Ebola Virus Disease3/3/2015 12:00:00 AM​The search continues for a treatment and vaccine with potential to control the Ebola virus. This Product Brief explores the available evidence on the Ebola vaccine candidate cAd3-EBO, developed by GlaxoSmithKline and the National Institutes of Health.
LightMix Ebola Zaire rRT-PCR Test (TIB Molbiol GmbH/Roche) for Diagnosing Ebola Virus Diseasehttps://www.ecri.org/components/ProductBriefs/Pages/14455.aspxLightMix Ebola Zaire rRT-PCR Test (TIB Molbiol GmbH/Roche) for Diagnosing Ebola Virus Disease1/23/2015 12:00:00 AM​This report looks at the literature for the LightMix® Ebola Zaire rRT-PCR test (TIB Molbiol/Roche), which has received Emergency Use Authorization from FDA for diagnosing Ebola virus disease.
Zmapp Monoclonal Antibody Cocktail (Mapp Biopharmaceutical/LeafBio, Inc.) for Treating Ebola Virus Diseasehttps://www.ecri.org/components/ProductBriefs/Pages/14370.aspxZmapp Monoclonal Antibody Cocktail (Mapp Biopharmaceutical/LeafBio, Inc.) for Treating Ebola Virus Disease11/20/2014 12:00:00 AM​We examine the literature on the ZMappTM, which is a drug under development that comprises three monoclonal antibodies to treat patients with Ebola virus disease. The drug combines a previously existing antibody cocktail and two from a different antibody cocktail called ZMab.
AVI 6002 (AVI-7537) Drug Therapy (Sarepta Therapeutics) for Treating Ebola Virus Diseasehttps://www.ecri.org/components/ProductBriefs/Pages/14371.aspxAVI 6002 (AVI-7537) Drug Therapy (Sarepta Therapeutics) for Treating Ebola Virus Disease11/18/2014 12:00:00 AM​We examine the published clinical evidence on how well AVI-6002 (Sarepta Therapeutics) Ebola virus disease affected patients.
Aethlon Hemopurifier (Aethlon Medical) for Purifying Blood Infected with Ebola or Other Hemorrhagic Viruseshttps://www.ecri.org/components/ProductBriefs/Pages/14369.aspxAethlon Hemopurifier (Aethlon Medical) for Purifying Blood Infected with Ebola or Other Hemorrhagic Viruses11/17/2014 12:00:00 AM​We explore the literature on the Aethlon Hemopurifier™ (Aethlon Medical, Inc.), which is intended to purify blood infected with Ebola or other hemorrhagic viruses.
BreastNext Comprehensive Testing Panel (Ambry Genetics Corp.) for Assessing Risk and Guiding Management of Hereditary Breast and Ovarian Cancerhttps://www.ecri.org/components/ProductBriefs/Pages/13528.aspxBreastNext Comprehensive Testing Panel (Ambry Genetics Corp.) for Assessing Risk and Guiding Management of Hereditary Breast and Ovarian Cancer4/28/2015 12:00:00 AMBreastNext™ uses a blood, saliva, or purified DNA sample to analyze a 17-gene panel for gene mutations, including BRCA1 and BRCA2, to assess the risk of breast and ovarian cancer in an individual suspected to be at high risk
OVA1 and ROMA Multivariate Biomarker Tests for Determining Malignancy Risk of a Pelvic Masshttps://www.ecri.org/components/ProductBriefs/Pages/11713.aspxOVA1 and ROMA Multivariate Biomarker Tests for Determining Malignancy Risk of a Pelvic Mass4/3/2015 12:00:00 AMOVA1®, an in vitro blood test of five biomarkers, and the Risk of Ovarian Malignancy Algorithm™ (ROMA™), an in vitro blood test of two biomarkers, are intended to help determine the type of surgeon to whom a woman should be referred once she has decided to undergo exploratory surgery to definitively diagnose a pelvic mass.
BRACAnalysis Test (Myriad Genetics, Inc.) for Assessing Risk of Hereditary Breast and Ovarian Cancerhttps://www.ecri.org/components/ProductBriefs/Pages/10412.aspxBRACAnalysis Test (Myriad Genetics, Inc.) for Assessing Risk of Hereditary Breast and Ovarian Cancer12/21/2014 12:00:00 AMThe BRACAnalysis® test uses a blood or cheek swab sample to identify BRCA1 and BRCA2 mutations. About 50% of hereditary breast cancers are associated with mutations in one of the BRCA genes.